The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
The identification of cancer-associated mutations in the tricarboxylic acid (TCA) cycle enzymes isocitrate dehydrogenases 1 and 2 (IDH1/2) highlights the prevailing notion that aberrant metabolic function can contribute to carcinogenesis. IDH1/2 normally catalyse the oxidative decarboxylation of iso...
मुख्य लेखकों: | Carbonneau, M, M Gagné, L, Lalonde, M, Germain, M, Motorina, A, Guiot, M, Secco, B, Vincent, E, Tumber, A, Hulea, L, Bergeman, J, Oppermann, U, Jones, R, Laplante, M, Topisirovic, I, Petrecca, K, Huot, M, Mallette, F |
---|---|
स्वरूप: | Journal article |
भाषा: | English |
प्रकाशित: |
Springer Nature
2016
|
समान संसाधन
-
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.
द्वारा: Chowdhury, R, और अन्य
प्रकाशित: (2011) -
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
द्वारा: Chowdhury, R, और अन्य
प्रकाशित: (2011) -
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
द्वारा: Chowdhury, R, और अन्य
प्रकाशित: (2011) -
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate
द्वारा: Teng, Xin, और अन्य
प्रकाशित: (2016) -
Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity
द्वारा: Mengyuan Cai, और अन्य
प्रकाशित: (2024-01-01)